Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-07-05
2005-07-05
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388200, C530S389300, C424S133100, C424S143100, C424S171100
Reexamination Certificate
active
06914129
ABSTRACT:
The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic reactions.
REFERENCES:
patent: 4629783 (1986-12-01), Cosand
patent: 4714759 (1987-12-01), Whitaker, Jr.
patent: 4861579 (1989-08-01), Meyer et al.
patent: 4940782 (1990-07-01), Rup et al.
patent: 5428133 (1995-06-01), Chang
patent: 5585089 (1996-12-01), Queen et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 255249 (1988-02-01), None
patent: 263655 (1988-04-01), None
patent: 58-156285 (1983-09-01), None
patent: WO 89/04834 (1989-06-01), None
patent: WO 89/06138 (1989-07-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/09968 (1991-07-01), None
Duncan et al., “Localization of the Binding Site for the Human High-Affinity Fc Receptor on IgG.”Nature332:563-564 (Apr. 7, 1988).
Jefferis et al., “Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFcγR) ”Molecular Immunology27(12):1237-1240 (1990).
Jones et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse.”Nature321:522-525 (May 29, 1986).
Nissim et al., “Fine specificity of the IgE Interaction with the Low and High Affinity Fc Receptor”J. Immunol. 150:1365-1374 (1993).
Baniyash et al., “Anti-IgE monoclonal antibodies directed at the Fcεreceptor binding site”Molecular Immunology25(8):705-711 (1998).
Baniyash et al., “Inhibition of IgE Binding to Mast Cells and Basophils by Monoclonal Antibodies to Murine IgE”European Journal of Immunology14:799-807 (1984).
Baniyash, “Immunochemical Characterization of the Interaction Between Immunoglobulin E and Its Receptor”Weizmann Institute of Science(Thesis) (May 1986).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth FActor-1 from Its Receptor-binding Activities by site-directed Mutagenesis of a Single Lysine Residue”Journal of Cell Biology111:2129-2138 (1990).
Burt et al., “Analysis of the interaction between rat immunoglobulin E and rat mast cells using anti-peptide antibodies”Molecular Immunology24(4):379-389 (1987).
Burt et al., “Inhibition of binding of rat IgE to rat mast cells by synthetic IgE peptides”European Journal of Immunology17:437-440 (1987).
Casale et al., “Recombinant Human Monoclonal Anti-IgE Therapy in Allergic Rhinitis”Journal Allergy Clinical Immunology(Abstract) 97(1):Part 3 (1996).
Conrad et al., “The Interaction of Human and Rodent IgE with the Human Basophil IgE Receptor”J. of Immunology130(1):327-333 (1983).
Conrad, D. H., “FcγRII/CD23: The low affinity receptor for IgE”Ann. Rev. Immunol.8:623-639 (1990).
Deisenhofer, J., “Crystallographic Refinement and Atomic Models of a Human Fc Fragment and its complex with Fragment B of Protein A fromStaphylococcus aureusat 2.9— and 2.8—A resolution”Biochemistry20(9):2361-2370 (Apr. 28, 1981).
Emery et al., “Humanised monoclonal antibodies for therapeutic applications”Exp. Opin. Invest. Drugs3(3):241-251 (1994).
Geha et al., “IgE sites relevant for binding to type 1 Fc epsilon(FCER) receptors on mast cells”J. Allergy&Clin. Immunol. (Abstract No. 20) 79(1):129 (1987).
Gillies et al., “Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities”Hum. Antibod. Hybridomas1(1):47-54 (1990).
Glennie et al., “Preparation and Performance of Bispecific F(ab'γ) 2 Antibody Containing Thiroether-Linked Fab'γ Fragments”J. Immunol.139(7):2367-2375 (Oct. 1, 1987).
Hakimi et al., “The αsubunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding”Journal of Biological Chemistry265(36):22079-22081 (1990).
Helm et al., “Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a reconbinant human ε-chain fragment of 76 amino acids”Proc. Natl. Acad. Sci.86:9465-9469 (Dec. 1989).
Helm et al., “Identification of the High Affinity Receptor Binding Region in Human Immunoglobulin E”Journal of Biological Chemistry271(13):7494-7500 (Mar. 29, 1996).
Helm et al., “The mast cell binding site on human immunoglobulin E”Nature331:180-183 (Jan. 14, 1988).
Hoffman, D. R., “Enzyme-linked immunosorbent assays (ELISA) for immunoglobulin E and blocking antibodies”Methods in Enzymology, Chapter 45, 73:656-666 (1981).
Hook et al., “Monoclonal Antibodies Defining Epitopes on Human IgE”Molecular Immunology28(6):631-639 (1991).
Ishizaka et al., “Mechanisms of passive sensitization III. Number of IgE Molecules and their Reseptor Sites on Human Basophil Granulocytes”J. Immunol. 111(2):500-511 (Aug. 1973).
Ishizaka, K., “Immunoglobulin E (IgE)”Methods in Enzymology116(Part II):76-94 (1985).
Jefferis, R., “Structure-function relationships in human immunoglobulins”Netherlands J. Medicine39:188-198 (1991).
KabatSequences of Proteins of Immunoglogical Interest(Fourth Ed.), 4th edition pp. 41-42, 167-168 (1987).
Kahan, “Immunosuppressive therapy”Current Opinion in Immunology4(5):553-560 (Oct. 1992).
Kulczycki et al., “The Intercation of IgE with Rat Basophilic Leukemia Cells, Evidence for Specific Binding of IgE”Journal of Experimental Medicine139:600-616 (1974).
Kumar et al., “Amino acid variations at a single residue in an autoimmune peptide, etc”.P.N.A.S. USA87:1337-1341 (Feb. 1990).
Kurokawa et al., “Expression of human immunoglobulin E ε chain cDNA in E. coli”Nucleic Acids Research11(10):3077-3085 (1983).
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities”Molecular&Cellular Biology8(3):1247-1252 (Mar. 1988).
Liu et al., “Expression of a Biologically active fragment of human IgE ε chain in Escherichia coli”Proc. Natl. Acad. Sci.81:5369-5373 (Sep. 1984).
Metzger and Kinet, “How Antibodies work: focus Fc receptors”FASEB J2(1):3-11 (Jan. 1988).
Neurath, A. R.. “Use of I25 I-labeled anti-3, 4-dinitrophenyl (DNP) antibodies as a general tracer in solid-phase radioimmunoassays”Methods in Enzymology73:127-138 (1981).
Nio et al., “Inhibition of histamine release by synthetic human IgE peptide fragments: structure-activity studies”Peptide Chemistrypp. 203-208 (1989).
Nissim et al., “Mapping of the high affinity Fcε receptor binding site to the third constant region domain of IgE”EMBO Journal10(1):101-107 (Jan. 1991).
Nissim et al., “The Use of Mouse/Human IgE Chimeras to Map the FceR Binding Site of IgE”Methods8:124-132 (1995).
Nitta et al., “Preliminary trial of specific targeting therapy against malignant glioma”Lancet335(8686):368-371 (Feb. 17, 1990).
Padlan et al., “A model of the Fc of immunoglobulin E”Molecular Immunology23(10):1063-1075 (1986).
Paul, W.E. ed.Fundamental Imunology, Raven Press, NY, 3rd edition pp. 822-826 (1993).
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor”Proc. Natl. Acad. Sci. USA86(24):10029-10033 (Dec. 1989).
Rao et al., “Characterization of a Monoclonal Antibody Directed Against the Murine B Lymphocyte Receptor for IgE”Journal of Immunology138(6):1845-1851 (Mar. 15, 1987).
Riechmann et al., “Reshaping human antibodies for therapy”Nature332(24):323-327 (Mar. 1988).
Riske et al., “High Affinity Human IgE Receptor (FcεRI). Analysis of functional Domains of the α-Subunit
Jardieu Paula M.
Presta Leonard G.
Blanchard David J
Genentech Inc.
Helms Larry R.
Svoboda Craig G.
LandOfFree
Anti-IgE antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IgE antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IgE antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3392604